In a turbulent market environment, VINC stock has reached its 52-week low, trading at $1.62, with technical indicators from InvestingPro showing the stock in oversold territory. This price level ...
Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting ...
Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Vincerx Pharma, Inc. (NasdaqCM: VINC) and Oqory, Inc. Pursuant to the terms of the ...
MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Vincerx (Nasdaq: VINC) for possible breaches of fiduciary duty and other violations of law in its transaction with the Oqory. Click here to ...
Vincerx Pharma announces early results for VIP943 and VIP236 in Phase 1 studies targeting hard-to-treat cancers, with complete responses seen in AML and HR-MDS patients and encouraging disease ...
Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback